RETEVMO
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
GNR judgment: CANDIDATE. Reference year: 2039. Anchor type: DS_EQUIVALENT_PATENT. Patent anchor: 2039-04-10. Exclusivity anchor: not recorded. Anchor date: 2039-04-10. Patent tail: no. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 10112942 | 2037-10-10 | DS/DP — | — | — | — | — | — | — |
| 10137124 | 2037-10-10 | U U-3450 | — | — | — | — | — | — |
| 10137124 | 2037-10-10 | U U-3951 | — | — | — | — | — | — |
| 10137124 | 2037-10-10 | U U-3949 | — | — | — | — | — | — |
| 10137124 | 2037-10-10 | U U-3950 | — | — | — | — | — | — |
| 10172851 | 2037-10-10 | U U-3450 | — | — | — | — | — | — |
| 10172851 | 2037-10-10 | U U-3949 | — | — | — | — | — | — |
| 10172851 | 2037-10-10 | U U-3951 | — | — | — | — | — | — |
| 10172851 | 2037-10-10 | U U-3950 | — | — | — | — | — | — |
| 10112942 | 2038-04-10 | — — | — | — | — | — | 2038-04-10 | — |
| 10112942 | 2038-04-10 | ORANGE_BOOK — | Y | N | TRUE_DS Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | — | 2038-04-10 | — |
| 10137124 | 2038-04-10 | — — | — | — | — | — | 2038-04-10 | — |
| 10137124 | 2038-04-10 | ORANGE_BOOK U-3450,U-3949,U-3950,U-3951 | N | Y | DS_EQUIVALENT Claim 1: RET dysregulated cancers without tumor-type limitation. | — | 2038-04-10 | — |
| 10172851 | 2038-04-10 | — — | — | — | — | — | 2038-04-10 | — |
| 10172851 | 2038-04-10 | ORANGE_BOOK U-3450,U-3949,U-3950,U-3951 | N | Y | DS_EQUIVALENT Claim 1: detecting RET dysregulation and treating RET-associated cancer; all label indications select RET alterations. | — | 2038-04-10 | — |
| 12138250 | 2038-10-10 | U U-3950 | — | — | — | — | — | — |
| 12138250 | 2038-10-10 | U U-3949 | — | — | — | — | — | — |
| 12138250 | 2038-10-10 | U U-3951 | — | — | — | — | — | — |
| 12138250 | 2038-10-10 | U U-3450 | — | — | — | — | — | — |
| 12138250 | 2039-04-10 | — — | — | — | — | — | 2039-04-10 | — |
| 12138250 | 2039-04-10 | ORANGE_BOOK U-3450,U-3949,U-3950,U-3951 | N | Y | DS_EQUIVALENT Independent claims 4 + 8 within the same patent: RET-associated thyroid cancer (including mutation-positive MTC) and any advanced/metastatic RET-fusion positive solid tumor jointly cover all label indications. | — | 2039-04-10 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| ODE* | — | 2027-05-08 | — | — | — | — | Source | |
| ODE* | — | 2027-05-08 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| M-311 | — | 2027-09-27 | — | — | — | — | Source | |
| M-311 | — | 2027-09-27 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| M-312 | — | 2027-09-27 | — | — | — | — | Source | |
| M-312 | — | 2027-09-27 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2027-11-08 | — | — | — | — | Source | |
| PED | — | 2027-11-08 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2028-03-27 | — | — | — | — | Source | |
| PED | — | 2028-03-27 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| ODE* | — | 2029-09-21 | — | — | — | — | Source | |
| ODE* | — | 2029-09-21 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2030-03-21 | — | — | — | — | Source | |
| PED | — | 2030-03-21 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| ODE* | — | 2031-05-29 | — | — | — | — | Source | |
| ODE* | — | 2031-05-29 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2031-11-29 | — | — | — | — | Source | |
| PED | — | 2031-11-29 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (5)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2038-04-10 | HISTORICAL_CONTEXT | Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | Source |
| PATENT | 2038-04-10 | HISTORICAL_CONTEXT | Claim 1: RET dysregulated cancers without tumor-type limitation. | Source |
| PATENT | 2038-04-10 | HISTORICAL_CONTEXT | Claim 1: detecting RET dysregulation and treating RET-associated cancer; all label indications select RET alterations. | Source |
| PATENT | 2039-04-10 | CANONICAL_ANCHOR | Independent claims 4 + 8 within the same patent: RET-associated thyroid cancer (including mutation-positive MTC) and any advanced/metastatic RET-fusion positive solid tumor jointly cover all label indications. | Source |
| REGULATORY_STATUS | 2039-04-10 | CANONICAL_DECISION | English description not available. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.